Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients

Worachart Insuwanno, Pattarachai Kiratisin, Anupop Jitmuang, Worachart Insuwanno, Pattarachai Kiratisin, Anupop Jitmuang

Abstract

Purpose: To study the clinical characteristics and factors associated with mortality of patients who had Stenotrophomonas maltophilia infections.

Patients and methods: We conducted a retrospective study to determine the clinical characteristics and factors associated with mortality for S. maltophilia infections among hospitalized adult patients at Siriraj Hospital. The clinical and microbiological data were collected from medical records December 2013-December 2016.

Results: Of 1221 subjects whose clinical samples grew S. maltophilia, 213 were randomly selected for chart review. One hundred patients with a true infection were analyzed. Their median age was 66 years; 47 were males; 46 were critically ill with a median APACHE II score of 18 (2-32); and 91 received antibiotic treatment, mainly with carbapenems (56%), before being diagnosed with a S. maltophilia infection. Pulmonary (53%) and bloodstream infections (25%) were the most common infections. The median length of hospitalization was 19 days before infection onset. The in-hospital mortality rate was 54%. The following factors were associated with mortality: a pre-existing respiratory infection (OR 6.28, 1.33-29.78; p.021); critical illness (OR 3.33, 1.45-7.62; p.005); multi-organ dysfunction (OR 2.44, 1.05-5.70; p.039); being on mechanical ventilation (OR 4.44, 1.90-10.39; p.001); concurrent immunosuppressive therapy (OR 2.67, 1.10-6.47; p.029); intravascular (OR 4.43, 1.79-10.92; p.001) and urinary catheterization (OR 4.83, 1.87-12.47; p.001); and serum albumin <3 g/dL (OR 4.13, 1.05-16.33; p.043). A multivariate analysis identified two independent factors associated with mortality: being on mechanical ventilation (OR 4.43, 1.86-10.59; p 0.001) and receiving concurrent immunosuppressive therapy (OR 2.26, 1.04-6.82; p 0.042).

Conclusion: S. maltophilia can cause nosocomial infections with high mortality, particularly in patients with a prolonged hospitalization. Concurrent immunosuppressive therapy and being on mechanical ventilation are the independent factors associated with a fatal outcome.

Keywords: Stenotrophomonas maltophilia infection; hospitalized patients; mortality.

Conflict of interest statement

The authors report no conflicts of interest in this work.

© 2020 Insuwanno et al.

References

    1. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41.
    1. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–323. doi:10.1016/S1473-3099(09)70083-0
    1. Fihman V, Le Monnier A, Corvec S, et al. Stenotrophomonas maltophilia–the most worrisome threat among unusual non-fermentative gram-negative bacilli from hospitalized patients: a prospective multicenter study. J Infect. 2012;64(4):391–398. doi:10.1016/j.jinf.2012.01.001
    1. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34(12):1653–1656. doi:10.1086/340707
    1. VanCouwenberghe CJ, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. Infect Control Hosp Epidemiol. 1997;18(5):316–321. doi:10.2307/30141224
    1. Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–108. doi:10.1016/j.jhin.2008.05.020
    1. Rattanaumpawan P, Ussavasodhi P, Kiratisin P, Aswapokee N. Epidemiology of bacteremia caused by uncommon non-fermentative gram-negative bacteria. BMC Infect Dis. 2013;13167.
    1. Jeon YD, Jeong WY, Kim MH, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia. Medicine (Baltimore). 2016;95(31):e4375. doi:10.1097/MD.0000000000004375
    1. Xun M, Zhang Y, Li BL, Wu M, Zong Y, Yin YM. Clinical characteristics and risk factors of infections caused by Stenotrophomonas maltophilia in a hospital in northwest China. J Infect Dev Ctries. 2014;8(8):1000–1005. doi:10.3855/jidc.4236
    1. Sanchez MB, Hernandez A, Martinez JL. Stenotrophomonas maltophilia drug resistance. Future Microbiol. 2009;4(6):655–660. doi:10.2217/fmb.09.45
    1. Vila J, Marco F. Interpretative reading of the non-fermenting gram-negative bacilli antibiogram. Enferm Infecc Microbiol Clin. 2002;20(6):304–310. doi:10.1016/S0213-005X(02)72803-6
    1. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.002
    1. Saugel B, Eschermann K, Hoffmann R, et al. Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients. Eur J Clin Microbiol Infect Dis. 2012;31(7):1419–1428. doi:10.1007/s10096-011-1459-8
    1. Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81(2):114–118. doi:10.1016/j.jhin.2012.02.008
    1. Samonis G, Karageorgopoulos DE, Maraki S, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One. 2012;7(5):e37375. doi:10.1371/journal.pone.0037375
    1. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004. Eur J Clin Microbiol Infect Dis. 2007;26(1):13–20. doi:10.1007/s10096-006-0243-7
    1. Del Toro MD, Rodriguez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore). 2002;81(3):228–239. doi:10.1097/00005792-200205000-00006
    1. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11(1):57–80.
    1. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis. 2002;35(3):228–235. doi:10.1086/341022
    1. Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996;22(3):508–512. doi:10.1093/clinids/22.3.508
    1. Lai CH, Chi CY, Chen HP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect. 2004;37(6):350–358.
    1. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years’ experience in a medical center in northern Taiwan. J Microbiol Immunol Infect. 2004;37(6):359–365.
    1. Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53. doi:10.1053/jinf.2002.0978
    1. Kwa AL, Low JG, Lim TP, Leow PC, Kurup A, Tam VH. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singapore. 2008;37(10):826–830.
    1. Chang LL, Lin HH, Chang CY, Lu PL. Increased incidence of class 1 integrons in trimethoprim/sulfamethoxazole-resistant clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 2007;59(5):1038–1039. doi:10.1093/jac/dkm034
    1. Ko JH, Kang CI, Cornejo-Juárez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis. Clin Microbiol Infect. 2019;25(5):546–554. doi:10.1016/j.cmi.2018.11.008
    1. Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1):176–182. doi:10.1128/AAC.01324-13
    1. Kim EJ, Kim YC, Ahn JY, et al. Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteremia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 2019;19(1):754. doi:10.1186/s12879-019-4394-4
    1. Sumida K, Chong Y, Miyake N, et al. Risk factors associated with Stenotrophomonas maltophilia bacteremia: a matched case-control study. PLoS One. 2015;10(7):e0133731. doi:10.1371/journal.pone.0133731

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться